Pervanadate Activation of Intracellular Kinases Leads to Tyrosine Phosphorylation and Shedding of Syndecan-1
Overview
Affiliations
Syndecan-1 is a transmembrane haparan sulphate proteoglycan that binds extracellular matrices and growth factors, making it a candidate to act between these regulatory molecules and intracellular signalling pathways. It has a highly conserved transmembrane/cytoplasmic domain that contains four conserved tyrosines. One of these is in a consensus sequence for tyrosine kinase phosphorylation. As an initial step to investigating whether or not phosphorylation of these tyrosines is part of a signal-transduction pathway, we have monitored the tyrosine phosphorylation of syndecan-1 by cytoplasmic tyrosine kinases in intact cells. Tyrosine phosphorylation of syndecan-1 is observed when NMuMG cells are treated with sodium orthovanadate or pervanadate, which have been shown to activate intracellular tyrosine kinases. Initial studies with sodium orthovanadate demonstrate a slow accumulation of phosphotyrosine on syndecan-1 over the course of several hours. Pervanadate, a more effective inhibitor of phosphatases, allows detection of phosphotyrosine on syndecan-1 within 5 min, with peak phosphorylation seen by 15 min. Concurrently, in a second process activated by pervanadate, syndecan-1 ectodomain is cleaved and released into the culture medium. Two phosphorylated fragments of syndecan-1 of apparent sizes 6 and 8 kDa remain with the cell after shedding of the ectodomain. The 8 kDa size class appears to be a highly phosphorylated form of the 6 kDa product, as it disappears if samples are dephosphorylated. These fragments contain the C-terminus of syndecan-1 and also retain at least a portion of the transmembrane domain, suggesting that they are produced by a cell surface cleavage event. Thus pervanadate treatment of cells results in two effects of syndecan-1: (i) phosphorylation of one or more of its tyrosines via the action of a cytoplasmic kinase(s) and (ii) cleavage and release of the ectodomain into the medium, producing a C-terminal fragment containing the transmembrane/cytoplasmic domain.
Zhu J, Li Z, Ji Z, Wu Y, He Y, Liu K Brain Pathol. 2021; 32(1):e13006.
PMID: 34286899 PMC: 8713524. DOI: 10.1111/bpa.13006.
Mapping proteolytic neo-N termini at the surface of living cells.
Weeks A, Byrnes J, Lui I, Wells J Proc Natl Acad Sci U S A. 2021; 118(8).
PMID: 33536314 PMC: 7923363. DOI: 10.1073/pnas.2018809118.
Yang J, LeBlanc M, Cano I, Saez-Torres K, Saint-Geniez M, Ng Y J Biol Chem. 2020; 295(19):6641-6651.
PMID: 32193206 PMC: 7212652. DOI: 10.1074/jbc.RA119.011192.
Dually modified transmembrane proteoglycans in development and disease.
Jenkins L, Horst B, Lancaster C, Mythreye K Cytokine Growth Factor Rev. 2018; 39:124-136.
PMID: 29291930 PMC: 5866756. DOI: 10.1016/j.cytogfr.2017.12.003.
Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer.
Zuo D, Chen Y, Li W, Liu R, He Y, Ren L Br J Cancer. 2014; 111(10):1965-76.
PMID: 25321193 PMC: 4229635. DOI: 10.1038/bjc.2014.493.